Moreover, a higher TGF-β signaling activation was also reported in the liver of NASH patients with fibrosis, when compared to patients with mild NAFLD without fibrosis [135]. This evidence concerns the gene TGFB1 and metabolic dysfunction-associated steatotic liver disease.